DBV DBV Technologies SA

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Market : NYSE Euronext Paris ISIN Code: FR 0010417345

Date Total number of shares Total number of voting rights
 



 



09/30/2024



  		 



 



96,501,526



  		 



Total gross of voting rights: 96,501,526
Total net* of voting rights: 96,199,467

* Net total = total number of voting rights attached to shares – shares without voting rights

Attachment



EN
14/10/2024

Underlying

DBVDBV Technologies SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DBV Technologies SA

 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway f...

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated ...

December 11, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information regarding the total number of voting rights and  total nu...

Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024 Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2024102,847,501Total gross of voting rights: 102,847,501Total net* of voting rights: 102,582,335 * Net total = total number of voting rights attached...

December 2, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

Information relative au nombre total des droits de vote et d’actions ...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024                                                                Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345   Date   Nombre total d’actions composant le capital social Nombre total de droits de vote 30/11/2024   102.847.501   ...

December 2, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per s...

November 11, 2024 1 EN
 PRESS RELEASE
Free
DBV DBV Technologie...

DBV Technologies Reports Third Quarter 2024 Financial Results

DBV Technologies Reports Third Quarter 2024 Financial Results Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024. Financial High...

November 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch